Skip to main content

IFNGR1 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1.

Be the first to review this product! Submit a review

Images

Western blot - Human IFNGR1 knockout HeLa cell line (AB265111), expandable thumbnail
  • Sanger Sequencing - Human IFNGR1 knockout HeLa cell line (AB265111), expandable thumbnail

Key facts

Cell type
HeLa
Species or organism
Human
Tissue
Cervix
Form
Liquid
Knockout validation
Sanger Sequencing, Western blot
Mutation description
Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1

Alternative names

AVP type II, AVP, type 2, Antiviral Protein Type II, Antiviral protein, type 2, CD 119, CD119 antigen, CDw119, FLJ45734, IFN gamma R, IFN gamma R alpha, IFN-gamma receptor 1, IFN-gamma-R1, IFNG R1, IFNGR, IFNGR 1, INGR1_HUMAN, Immune interferon receptor 1, Immune interferon receptor for, Interferon gamma receptor 1, Interferon gamma receptor alpha chain, Interferon gamma receptor alpha chain precursor

Recommended products

IFNGR1 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1.

Key facts

Cell type
HeLa
Form
Liquid
Mutation description
Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1
Antibiotic resistance
Puromycin 1µg/mL
Disease
Adenocarcinoma
Concentration
Loading...

Properties

Gene name
IFNGR1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Zygosity
Homozygous

Quality control

STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level
EU: 2 US: 2
Adherent/suspension
Adherent
Gender
Female

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium
DMEM (High Glucose) + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Storage

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Notes

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

The IFNGR1 protein also known as Interferon Gamma Receptor 1 is an integral component of the cell surface receptor for interferon-gamma (IFN-γ). It possesses a mass of approximately 53 kDa. IFNGR1 is expressed in various cell types including immune cells such as T cells and macrophages and is also present in other cell lines like HEK 293. This receptor binds to its specific ligand IFN-γ initiating a series of intracellular events that are essential for immune response modulation.

Biological function summary

IFNGR1 functions as part of the interferon-gamma receptor complex working alongside the IFNGR2 subunit. This interaction with IFNGR2 is important for the receptor to properly transmit signals inside the cell. The binding of interferon-gamma to this receptor complex activates the JAK-STAT signaling pathway promoting the transcription of genes that enhance the antimicrobial activity of immune cells and regulate cellular immunity.

Pathways

The IFNGR1 protein plays an important role in the JAK-STAT signaling pathway which is critical for mediating responses to interferon-gamma. Upon activation by IFN-γ IFNGR1 recruits JAK kinases leading to the phosphorylation of STAT1 a significant transcription factor. STAT1 then dimerizes and translocates to the nucleus where it induces the expression of genes involved in immune defense and inflammation. This process is vital for the body's ability to handle infections and other immunological challenges.

Associated diseases and disorders

IFNGR1 is associated with susceptibility to infections and certain immune-related disorders. Mutations or deficiencies in IFNGR1 can lead to Mendelian Susceptibility to Mycobacterial Disease (MSMD) where individuals show increased vulnerability to mycobacterial infections. Additionally improper signaling through IFNGR1 is linked to chronic granulomatous disease which can involve defective functioning of the NADPH oxidase complex. Understanding IFNGR1's function and interactions is important for exploring new therapeutic strategies for these disorders.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

2 product images

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com